rms with the U.S. Food and Drug Administration over plans for crucial clinical trials for its anti-radiation sickness drug.The agreement, outlined in an advice letter from the FDA, could remove what had been a major hurdle in Cleveland BioLabs' quest to obtain funding from federal or other funding sources that had been reluctant to commit more money to the company to fund its essential studies unt